Our Science – Gulley Website
James L. Gulley, M.D., Ph.D.
Selected Publications |
 |
| 1)
Schlom J, Hodge JW, Palena C, Greiner JW, Tsang KY, Farsaci B, Madan RA, Gulley JL. Prendergast G, Jaffee E, eds. Recombinant TRICOM-based therapeutic cancer vaccines: lessons learned. In: Cancer Immunotherapy. Elsevier; 2013. In Press. [Book Chapter] |
|
| 2)
Schlom J, Palena C, Gulley JL, Greiner JW, Tsang KY, Madan RA, Hodge JW. Lattime E, Gerson SL, eds. The use of T-cell costimulation to enhance the immunogenicity of tumors. In: Gene Therapy of Cancer: Translational Approaches from Preclinical Studies to Clinical Implementation, Third Edition. Elsevier; 2013. In Press. [Book Chapter] |
|
| 3)
Huang J, Jochems C, Anderson AA, Talaie T, Jales A, Madan RA, Hodge JW, Tsang KY, Liewehr DJ, Steinberg SM, Gulley JL, Schlom J. Soluble CD27-pool in humans may contribute to T-cell activation and tumor immunity. J Immunol. 2013. In Press. [Journal] |
|
| 4)
Fallon J, Gulley JL. World Vaccine Trials Congress 2012 Conference Summary] (World Vaccine Trials Congress 2012). . In Press. [Meeting Proceeding] |
|
| 5)
Bilusic M, Madan R, Gulley JL. Curiel T, eds. Issues in pre-clinical models, clinical trial design and analytical considerations in developing and evaluating novel cancer immunotherapies. In: Cancer Immunotherapy: Paradigms, Practice and Promise. New York: Springer Science+Business Media; 2013. p. 455-474 [Book Chapter] |
|
| 6)
Singh N, Hodge J, Madan R, Gulley JL. Shurin MR, Umansky V, Malyguine A, eds. Combining vaccines with therapies that render tumor cells more susceptible to immune mediated killing. In: The Tumor Immunoenvironment. Netherlands: Springer; 2013. p. 621-642, Chapter 27 [Book Chapter] |
|
| 7)
Madan RA, Gulley JL, Kantoff PW. Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies. Cancer J. 19: 50-8, 2013. [Journal] |
|
| 8)
Madan R, Gulley JL, Kantoff PW. Demystifying immunotherapy in prostate cancer: Understanding current and future treatment strategies. Cancer Journal (United States). 19(1): 50-58, 2013. [Journal] |
|
| 9)
Singh N, Madan RA, Gulley JL. Ipilimumab in prostate cancer. Expert Opin Biol Ther. 13: 303-13, 2013. [Journal] |
|
| 10)
Dahut WL, Madan RA, Karakunnel JJ, Adelberg D, Gulley JL, Turkbey IB, Chau CH, Spencer SD, Mulquin M, Wright J, Parnes HL, Steinberg SM, Choyke PL, Figg WD. Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. BJU Int. 2013. [Journal] |
|
| Click Here to View Expanded Bibliography. |
This page was last updated on 4/29/2013.
